Effects of peginterferon alfa-2b (peg-intron): A Synthesis of Findings from 27 Studies

  1. Home
  2. Effects of peginterferon alfa-2b (peg-intron)
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of peginterferon alfa-2b (peg-intron): A Synthesis of Findings from 27 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of peginterferon alfa-2b (peg-intron): A Synthesis of Findings from 27 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Peginterferon alfa-2b (peg-intron) has been shown to be an effective treatment for a variety of diseases, including chronic hepatitis B, chronic hepatitis C, polycythemia vera, osteosarcoma, melanoma, and renal cell carcinoma.

In the treatment of chronic hepatitis B, a study ( 12 ) found that HBcrAg is useful for predicting HBeAg seroconversion. Another study ( 18 ) found that peg-intron is an effective treatment for HBeAg-positive chronic hepatitis B patients in China. A study ( 16 ) found that intensifying treatment with peg-intron in patients coinfected with HIV and HBV genotypes H or G who are being treated with a tenofovir/emtricitabine-containing regimen may be effective.

In the treatment of chronic hepatitis C, a study ( 27 ) found that peg-intron had comparable safety and efficacy to albinterferon alfa-2b in HIV/HCV genotype 1 coinfected patients. Another study ( 19 ) found that peginterferons alfa-2a and alfa-2b had comparable efficacy in patients infected with hepatitis C virus (HCV) genotype 1. A study ( 24 ) found that daclatasvir with peg-intron alfa-2a or alfa-2b may be beneficial for the treatment of chronic HCV genotype 1 infection. A study ( 22 ) found that telaprevir with peginterferon/ribavirin was effective in treating HCV infection that aggressively recurs after orthotopic liver transplant (OLT). A study ( 14 ) found that vaniprevir with peg-intron alfa-2b and ribavirin was more effective than PR alone for the treatment of HCV genotype 1 infection in treatment-naive Japanese patients. A study ( 13 ) found that vaniprevir with peg-intron alfa-2b and ribavirin was effective for Japanese patients with HCV genotype 1 infection who had previously failed treatment with interferon-based regimens. A study ( 25 ) found that infections during peg-intron/ribavirin therapy were associated with the magnitude of decline in absolute lymphocyte count. A study ( 17 ) found that peg-intron with ribavirin was clinically effective and cost-effective for the treatment of chronic hepatitis C in children and young people. A study ( 11 ) found that peg-intron with ribavirin was effective for people with ongoing injecting drug use or receiving opioid substitution therapy (OST) with HCV genotypes 2/3 infection. A study ( 10 ) found that entecavir was a promising drug for HBV-related glomerulopathy, especially in IFN-resistant cases.

In the treatment of polycythemia vera, a study ( 5 ) found that ropeginterferon alfa-2b was effective in maintaining hematocrit on target levels in low-risk patients with polycythemia vera compared to standard phlebotomy. A study ( 7 ) compared the effectiveness of different therapeutic strategies in patients with polycythemia vera (PV) and essential thrombocythemia (ET). A study ( 2 ) found that ropeginterferon alfa-2b was promising for the treatment of adults with polycythemia vera. A study ( 3 ) found that ropeginterferon alfa-2b, a novel long-acting pegylated interferon alfa-2b, had a favorable safety profile, pharmacokinetics, and pharmacodynamics. A study ( 6 ) found that ropeginterferon alfa-2b demonstrated remarkable long-term hematological response and sustained JAK2V617F allele burden reduction.

In the treatment of osteosarcoma, a study ( 15 ) found that pegylated interferon alfa-2b maintenance therapy might improve outcomes for patients with resectable high-grade osteosarcoma who showed good histologic response to induction chemotherapy.

In the treatment of melanoma and renal cell carcinoma, a study ( 9 ) found that pembrolizumab combined with peg-intron showed promising antitumor activity in patients with advanced melanoma or renal cell carcinoma.

In the treatment of COVID-19, a study ( 4 ) found that peg-intron alfa-2b was effective and safe in subjects with moderate COVID-19 when used with the standard of care.

Benefits and Risks

Benefits Summary

Peg-intron has been shown to be an effective treatment for a variety of diseases, including chronic hepatitis B, chronic hepatitis C, polycythemia vera, osteosarcoma, melanoma, and renal cell carcinoma. In particular, it may be useful for predicting HBeAg seroconversion in chronic hepatitis B. In chronic hepatitis C, peg-intron has been shown to have comparable safety and efficacy to albinterferon alfa-2b in HIV/HCV genotype 1 coinfected patients. In polycythemia vera, it has been shown to be effective in maintaining hematocrit on target levels in low-risk patients compared to standard phlebotomy.

Risks Summary

Peg-intron can cause a number of side effects, including flu-like symptoms, fatigue, fever, headache, nausea, and vomiting. More serious side effects, such as a decrease in blood cells, inflammation of the liver, and thyroid problems, have also been reported. If you are using peg-intron, it is important to understand these risks and use the medication safely as directed by your doctor.

Comparison Between Studies

Similarities

These studies suggest that peg-intron may be an effective treatment for a variety of diseases. They also show that there are risks associated with the use of peg-intron.

Differences

It is difficult to directly compare these studies because they differ in their target diseases, treatment methods, and evaluation methods. However, many of these studies suggest that peg-intron is an effective treatment.

Consistency and Contradictions in Results

These studies suggest that peg-intron may be an effective treatment for a variety of diseases. However, there are also risks associated with its use. While these studies suggest that peg-intron is an effective treatment, the use of peg-intron should be carefully considered on a case-by-case basis.

Notes on Practical Application

Peg-intron may be an effective treatment for a variety of diseases, but its use should be carefully considered on a case-by-case basis. It is important to understand the risks and benefits of using peg-intron and to use the medication safely as directed by your doctor.

Limitations of Current Research

While these studies suggest that peg-intron may be an effective treatment for a variety of diseases, its effects may vary depending on the individual patient. These studies have not adequately investigated the long-term effects of peg-intron. Further research on the long-term effects of peg-intron is needed.

Future Research Directions

Research on the long-term effects of peg-intron is needed. Research is also needed to investigate the effects of peg-intron on a variety of diseases in more detail. Research on combination therapy involving peg-intron is particularly important.

Conclusion

Peg-intron may be an effective treatment for a variety of diseases, but its use should be carefully considered on a case-by-case basis. It is important to understand the risks and benefits of using peg-intron and to use the medication safely as directed by your doctor. Research on the long-term effects of peg-intron is needed.

Literature analysis of 27 papers
Positive Content
23
Neutral Content
2
Negative Content
2
Article Type
11
0
1
3
27
1.

Tolerance and biological activity of pentosan polysulfate after intramuscular or subcutaneous administration for ten days in human volunteers.

Author: SiéP, AlbaredeJ L, RobertM, BoulouxC, LansenJ, ChigotC, CorrellS, ThouvenotJ P, BoneuB

Good tolerance
Liver enzyme elevation
Platelet reduction

Pentosan polysulfate (PPS) is a drug that can be used to treat certain medical conditions. This study investigated the tolerance and pharmacological activity of PPS in 30 healthy volunteers. PPS was well tolerated, with the most common side effects being increased transaminase levels and decreased platelet counts. The study found that PPS significantly prolonged the activated partial thromboplastin time (APTT) and induced a weak but significant circulating anti-Xa activity.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera.

Author: KrecakIvan, SkelinMarko, VerstovsekSrdan

Disease-modifying activity
Side-effects

Interferons (IFNs) have shown potential for treating polycythemia vera (PV). While clinical trials demonstrated promising hematological and molecular responses, high discontinuation rates due to side effects are a concern.

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

3.

Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial.

Author: HuangYi-Wen, QinAlbert, FangJane, WangTing-Fang, TsaiChung-Wei, LinKo-Chung, TengChing-Leou, LaroucheRichard

Pharmacokinetic profile
Safety profile

Ropeginterferon alfa-2b, a novel long-acting pegylated interferon alfa-2b, was safe and well tolerated up to a dose of 270 μg. Ropeginterferon alfa-2b had higher drug exposures and a similar safety profile compared to pegylated IFN alfa-2a at the same dose level.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study.

Author: PanditAnuja, BhalaniNirav, BhushanB L Shashi, KoradiaParshottam, GargiyaShweta, BhomiaVinay, KansagraKevinkumar

COVID-19 treatment
PEG IFN-α2b efficacy
Adverse events

Pegylated interferon alfa-2b (PEG IFN-α2b) along with standard of care (SOC) showed a significant improvement in clinical status on day 15 in subjects with moderate COVID-19 compared to SOC alone. This is likely due to faster viral reduction with PEG IFN-α2b treatment.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

5.

Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.

Author: BarbuiTiziano, VannucchiAlessandro Maria, De StefanoValerio, MasciulliArianna, CarobbioAlessandra, FerrariAlberto, GhirardiArianna, RossiElena, CiceriFabio, BonifacioMassimiliano, IurloAlessandra, PalandriFrancesca, BenevoloGiulia, PaneFabrizio, RiccoAlessandra, CarliGiuseppe, CaramellaMarianna, RapezziDavide, MusolinoCaterina, SiragusaSergio, RumiElisa, PatriarcaAndrea, CascavillaNicola, MoraBarbara, CacciolaEmma, MannarelliCarmela, LoscoccoGiuseppe Gaetano, GuglielmelliPaola, BettiSilvia, LunghiFrancesca, ScaffidiLuigi, BucelliCristina, VianelliNicola, BelliniMarta, FinazziMaria Chiara, TognoniGianni, RambaldiAlessandro

Stable haematocrit
Neutropenia
Skin symptoms

Ropeginterferon alfa-2b, when added to the standard phlebotomy regimen, was safe and effective in steadily maintaining haematocrit values on target in low-risk patients with polycythaemia vera.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

6.

A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.

Author: IllésÁrpád, PinczésLászló Imre, EgyedMiklós

Improved tolerability
PV treatment
Symptomatic splenomegaly

Ropeginterferon alfa-2b is a new treatment option for polycythemia vera that shows improved tolerability and efficacy in reducing JAK2V617F allele burden.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

7.

Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.

Author: MelikyanA L, SubortsevaI N, GilyazitdinovaE A, KoloshejnovaT I, PustovayaE I, EgorovaE K, KovriginaA M, SudarikovA B, AbdullaevA O, LomaiaE G, SiordiyaN T, ZaritskeyA Yu, SavchenkoV G

Clinical responses
ET treatment
PV treatment
Hair loss
Hematologic adverse events
Local reactions
Pulmonary embolism
Skin toxicity

Treatment with ce-pegiterferone alpha-2b (ce-pegalpha-INF-α-2b) was highly effective in patients with polycythemia vera (PV) and essential thrombocythemia (ET), with most patients achieving clinical and hematological responses. The safety profile was acceptable.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

8.

A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron<sup>&#174;</sup> (Peginterferon alfa-2b) and Actimmune<sup>&#174;</sup> (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer.

Author: GreenDaniel S, NunesAna T, David-OcampoVirginia, EkwedeIrene B, HoustonNicole D, HighfillSteven L, KhuuHanh, StroncekDavid F, SteinbergSeth M, ZoonKathryn C, AnnunziataChristina M

Ovarian cancer treatment
Ovarian cancer recurrence

This study proposes a novel approach to treating ovarian cancer using locoregional immune therapy with interferons and monocytes. The method aims to create a pro-inflammatory environment at the site of disease to kill malignant cells.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., IntramuralFunding provided by the NIH for research projects within the NIH.

Language : English

9.

Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.

Author: AtkinsMichael B, HodiF Stephen, ThompsonJohn A, McDermottDavid F, HwuWen-Jen, LawrenceDonald P, DawsonNancy A, WongDeborah J, BhatiaShailender, JamesMarihella, JainLokesh, RobeySeth, ShuXinxin, Homet MorenoBlanca, PeriniRodolfo F, ChoueiriToni K, RibasAntoni

Melanoma treatment
RCC treatment
Adverse events

Pembrolizumab combined with ipilimumab showed promising antitumor activity and was tolerable in patients with advanced melanoma or renal cell carcinoma. The combination of pembrolizumab and PEG-IFN had limited antitumor activity in this population.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Successful Use of Entecavir in Hepatitis B-associated Membranous Nephropathy.

Author: MahajanVidushi, D'CruzSanjay, NadaRitambara, SachdevAtul

Entecavir effective
HBV-related glomerulopathy treatment
IFN resistance

This case study details a 7-year-old boy with HBV-related membranous nephropathy (MN) who failed to respond to peginterferon alfa-2b treatment. However, he achieved remission and seroconversion after 3 months of entecavir therapy. This suggests that entecavir is a promising drug for HBV-related glomerulopathy, especially in IFN-resistant cases.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

11.

Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.

Author: GrebelyJason, DalgardOlav, CunninghamEvan B, HajarizadehBehzad, FosterGraham R, BruggmannPhilip, ConwayBrian, BackmundMarkus, RobaeysGeert, SwanTracy, AminJanaki, MarksPhilippa S, QuieneSophie, ApplegateTanya L, WeltmanMartin, ShawDavid, DunlopAdrian, HellardMargaret, BruneauJulie, MidgardHåvard, BourgeoisStefan, StaehelinCornelia, DoreGregory J,

Effective treatment
None mentioned

This study examines the efficacy of response-guided therapy for chronic hepatitis C virus (HCV) infection among people with ongoing injecting drug use or receiving opioid substitution therapy (OST). The study aims to identify predictors of treatment response and address the limited data available on HCV treatment in this population.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

12.

HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b.

Author: MaHui, YangRui-Feng, LiXiao-He, JinQian, WeiLai

HBeAg seroconversion
Chronic hepatitis B

A study of 58 chronic hepatitis B patients found that serum hepatitis B virus core-related antigens (HBcrAg) levels declined during treatment. HBcrAg levels were found to be a good predictor of HBeAg seroconversion, but the positive predictive values were not satisfactory.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

13.

Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.

Author: KumadaHiromitsu, MochidaSatoshi, SuzukiFumitaka, ChayamaKazuaki, KarinoYoshiyasu, NakamuraKeisuke, FujimotoGo, HoweAnita Y M, LudmererSteve W, MobasheryNiloufar

HCV treatment

This study evaluated the safety and effectiveness of vaniprevir in combination with peginterferon alfa-2b and ribavirin for treating hepatitis C virus (HCV) genotype 1 infection in Japanese patients who had previously failed treatment with interferon-based regimens.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

14.

Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study.

Author: HayashiNorio, NakamutaMakoto, TakeharaTetsuo, KumadaHiromitsu, TakaseAkiko, HoweAnita Yee Mei, LudmererSteven W, MobasheryNiloufar

HCV treatment
Viral suppression

This phase III study evaluated the safety and efficacy of vaniprevir in combination with peginterferon alfa-2b and ribavirin (PR) for 24 weeks compared with PR alone for 48 weeks in treatment-naive Japanese patients with HCV genotype 1 infection. Vaniprevir is a potent macrocyclic hepatitis C virus (HCV) nonstructural protein 3/4A protease inhibitor.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

15.

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.

Author: BielackStefan S, SmelandSigbjørn, WhelanJeremy S, MarinaNeyssa, JovicGordana, HookJane M, KrailoMark D, GebhardtMark, PápaiZsuzsanna, MeyerJames, NadelHelen, RandallR Lor, DeffenbaughClaudia, NagarajanRajaram, BrennanBernadette, LetsonG Douglas, TeotLisa A, GoorinAllen, BaumhoerDaniel, KagerLeo, WernerMathias, LauChing C, Sundby HallKirsten, GelderblomHans, MeyersPaul, GorlickRichard, WindhagerReinhard, HelmkeKnut, ErikssonMikael, HoogerbruggePeter M, SchombergPaula, TunnPer-Ulf, KühneThomas, JürgensHeribert, van den BergHenk, BöhlingTom, PictonSusan, RenardMarleen, ReichardtPeter, GerssJoachim, Butterfass-BahloulTrude, MorrisCarol, HogendoornPancras C W, SeddonBeatrice, CalaminusGabriele, MichelagnoliMaria, DhoogeCatharina, SydesMatthew R, BernsteinMark,

Improved event-free survival
Refusal of treatment
Toxicity

MAP plus IFN-α-2b was not statistically different from MAP alone in treating osteosarcoma. A considerable proportion of patients never started IFN-α-2b or stopped prematurely.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
WebcastA live or recorded video or audio broadcast distributed over the Internet.

Language : English

16.

Intensification of treatment with pegylated interferon alfa in patients coinfected with HIV and HBV genotype H or G being treated with a tenofovir/emtricitabine-containing regimen.

Author: Mata-MarínJosé Antonio, Mata-MarínLuis Alberto, Arroyo-AnduizaCarla Ileana, Huerta-GarcíaGloria, Sandoval-RamirezJ L, Manjarrez-TellezBulmaro, Gaytán-MartínezJ E

HBV treatment

Intensification with pegylated interferon (PEG-IFN) alfa-2a or alfa-2b may be effective in HBV/HIV-coinfected patients treated with tenofovir/emtricitabine (TDF/FTC) in Mexico.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

17.

The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation.

Author: HartwellDebbie, CooperKeith, FramptonGeoff K, BaxterLouise, LovemanEmma

Cost-effective
Effective therapy
Poor evidence quality

Treatment of children and young people with peginterferon alfa-2a or -2b in combination with ribavirin may be an effective therapy for chronic hepatitis C. Peginterferon alfa-2a was more cost-effective than peginterferon alfa-2b.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

18.

Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: a randomized trial.

Author: ChengJun, WangYuming, HouJinlin, LuoDuande, XieQing, NingQin, RenHong, DingHuiguo, ShengJifang, WeiLai, ChenShijun, FanXiaoling, HuangWenxiang, PanChen, GaoZhiliang, ZhangJiming, ZhouBoping, ChenGuofeng, WanMobin, TangHong, WangGuiqiang, YangYuxiu, MohamedRosmawati, GuanRichard, LeeTzong-Hsi, ChangWen-Hsiung, ZhenfeiHuang, YeZhang, XuDaozhen

Increased HBe seroconversion
Increased HBeAg loss
Treatment discontinuation

Peginterferon alfa-2b 1.5μg/kg/wk for 48 weeks was found to be more efficacious than 1.0 and 1.5μg/kg/wk for 24 weeks in Chinese patients with HBeAg-positive chronic hepatitis B.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.

Author: BerakHanna, LaskusTomasz, Kołakowska-RządzkaAnna, WasilewskiMarek, StańczakJanusz J, BardadinKrzysztof, Walewska-ZieleckaBożena, HorbanAndrzej

Hepatitis C virus

Peginterferon alfa-2a and alfa-2b showed similar efficacy in treating patients infected with HCV genotype 1. SVR was associated with low fibrosis stage and low serum HCV RNA level.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

20.

Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C.

Author: HondaTakashi, IshigamiMasatoshi, MasudaHiroko, IshizuYoji, KuzuyaTeiji, HayashiKazuhiko, ItohAkihiro, HirookaYoshiki, NakanoIsao, IshikawaTetsuya, UranoFumihiro, YoshiokaKentaro, ToyodaHidenori, KumadaTakashi, KatanoYoshiaki, GotoHidemi

HCC prevention

This study examined the effects of peginterferon and ribavirin combination therapy on preventing hepatocellular carcinoma (HCC) in older patients with chronic hepatitis C (CH-C). The study aims to determine if this therapy can reduce the risk of developing HCC in this aging population.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

21.

A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin.

Author: HsuChing-Sheng, HsuShih-Jer, LinHans Hsienhong, TsengTai-Chung, WangChia-Chi, ChenDing-Shinn, KaoJia-Horng

Hepatitis C treatment
Insulin resistance

This pilot study investigated the impact of add-on oral hypoglycemic agents on sustained virological response in patients with chronic hepatitis C and insulin resistance.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

22.

Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant.

Author: KwoPaul Y, GhabrilMarwan, LacerdaMarco A, Joseph TectorAlfred, FridellJonathan A, ViannaRodrigo

Hepatitis C clearance
Anemia
Growth factor requirements

Telaprevir added to peginterferon/ribavirin led to significant clearance rates in null responders to peginterferon/ribavirin with advanced fibrosis post-orthotopic liver transplant (OLT).

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

23.

A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.

Author: SuzukiFumitaka, ToyotaJoji, IkedaKenji, ChayamaKazuaki, MochidaSatoshi, HayashiNorio, IshikawaHiroki, MiyagoshiHidetaka, HuWenhua, McPheeFiona, HughesEric A, KumadaHiromitsu

HCV treatment
High SVR24 rate
Adverse events
Virological failure

This randomized, double-blind study found that daclatasvir 60 mg combined with peginterferon alfa-2b and ribavirin achieved a high rate of sustained virological response 24 weeks post-treatment (SVR24) in treatment-naive patients with HCV genotype 1 infection. However, regimens with greater antiviral potency are needed for prior non-responders.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

24.

Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.

Author: McPheeFiona, HernandezDennis, ZhouNannan, YuFei, UelandJoseph, MonikowskiAaron, ChayamaKazuaki, ToyotaJoji, IzumiNamiki, YokosukaOsamu, KawadaNorifumi, OsakiYukio, HughesEric A, WatanabeHideaki, IshikawaHiroki, KumadaHiromitsu

HCV treatment
High SVR24 rate
Resistance development

Daclatasvir (DCV) plus peginterferon alfa-2a/ribavirin or alfa-2b/ribavirin was effective in treating patients with chronic HCV genotype 1b infection. Virological failure was associated with the emergence of NS5A resistance variants, which persisted at the end of the study.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

25.

Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study.

Author: MeliaMichael T, BräuNorbert, PoordadFred, LawitzEric J, ShiffmanMitchell L, McHutchisonJohn G, MuirAndrew J, GallerGreg W, NybergLisa M, LeeWilliam M, SchiffEugene, LongJianmin, NovielloStephanie, BrassClifford A, PediconeLisa D, SulkowskiMark S

Myelosuppression

This analysis investigated the incidence and risk factors for infections during pegylated interferon (peg-IFN)/ribavirin (RBV) therapy for hepatitis C virus. It examined the relationship between infection risk and decreases in leukocyte lines.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

26.

Addicts with chronic hepatitis C: difficult to reach, manage or treat?

Author: ZaniniBarbara, BeniniFederica, PigozziMarie Graciella, FurbaPatrizia, GiacòErnesto, CinquegranaAntonia, FasoliMariagrazia, LanziniAlberto

CHC treatment possible in addicts

Drug addicts with chronic hepatitis C (CHC) can be successfully treated in a multidisciplinary setting using standard antiviral combination therapy, despite a high prevalence of host and viral characteristics negatively affecting treatment response.

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

27.

Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients.

Author: OsinusiAnu, BonDimitra, NelsonAmy, LeeYu-Jin, PooniaSeerat, ShivakumarBhavana, CaiShu Yi, WoodBrad, HaagmansBart, LempickiRichard, HerrmannEva, SnellerMichael, PolisMichael, MasurHenry, KottililShyam

Blunted host response
Modest antiviral effect

This study compared the safety, tolerability, viral kinetics, and host responses of three different interferon formulations in patients coinfected with HIV and HCV. The study found that all three formulations exhibited comparable safety, tolerability, and efficacy profiles, suggesting that different interferon formulations may be equally effective in this population.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., IntramuralFunding provided by the NIH for research projects within the NIH.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.